Maglasang, Jake Michael P.
HRN: 26-05-57 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/17/2024
CEFUROXIME 500MG (TAB)
10/17/2024
10/24/2024
ORAL
500mg
Q12
Abrasion Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes